Tandem Diabetes Care Inc (NASDAQ:TNDM) Director Richard P. Valencia acquired 1,300 shares of Tandem Diabetes Care stock in a transaction that occurred on Monday, November 5th. The shares were purchased at an average cost of $37.75 per share, with a total value of $49,075.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Shares of NASDAQ:TNDM opened at $37.19 on Friday. Tandem Diabetes Care Inc has a fifty-two week low of $2.14 and a fifty-two week high of $52.55.
Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings results on Thursday, November 1st. The medical device company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.28). Tandem Diabetes Care had a negative return on equity of 204.32% and a negative net margin of 93.07%. The company had revenue of $46.30 million during the quarter, compared to analyst estimates of $42.71 million. During the same period in the prior year, the firm earned ($3.09) EPS. Tandem Diabetes Care’s quarterly revenue was up 71.5% on a year-over-year basis. As a group, equities research analysts anticipate that Tandem Diabetes Care Inc will post -1.35 EPS for the current fiscal year.
A number of analysts recently issued reports on TNDM shares. Oppenheimer set a $31.00 price objective on Tandem Diabetes Care and gave the company a “buy” rating in a research report on Tuesday, July 31st. ValuEngine raised Tandem Diabetes Care from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, September 4th. Zacks Investment Research raised Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $40.00 price objective for the company in a research report on Friday, October 5th. Craig Hallum set a $59.00 price objective on Tandem Diabetes Care and gave the company a “buy” rating in a research report on Friday, November 2nd. Finally, Robert W. Baird reissued a “buy” rating and set a $31.00 price objective on shares of Tandem Diabetes Care in a research report on Monday, July 23rd. Four analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $44.27.
Tandem Diabetes Care Company Profile
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.
Featured Story: What are Institutional Investors?
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.